Related Experiment Video
Updated: Dec 5, 2025
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Immune-Directed Molecular Imaging Biomarkers
Neeta Pandit-Taskar1, Michael A Postow2
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Abstract:
Imaging has played a critical role in the management of patients with cancer. Novel therapies are emerging rapidly; however, they are effective only in some patients. With the advent of new targeted therapeutics and immunotherapy, the limitations of conventional imaging methods are becoming more evident. FDG-PET imaging is restricted to the optimal assessment of immune therapies. There is a critical unmet need for pharmacodynamic and prognostic imaging biomarkers. Radiolabeled antibodies or small molecules can allow for specific assessment of targets in expression and concentration. Several such imaging agents have been under preclinical development. Early human studies with radiolabeled monoclonal antibodies or small molecules targeted to the epidermal growth factor receptor pathway have shown potential; targeted imaging of CA19.9 and CA-IX and are being further explored. Immune-directed imaging agents are highly desirable as biomarkers and preliminary studies with radiolabeled antibodies targeting immune mechanisms appear promising. While novel agents are being developed, larger well-designed studies are needed to validate the role of these agents as biomarkers in the clinical management of patients.
Insights
New imaging biomarkers are needed for cancer therapies. Radiolabeled antibodies and small molecules show promise for assessing treatment effectiveness and patient outcomes in oncology.
Area of Science:
- Oncology
- Medical Imaging
- Biomarker Discovery
Background:
- Conventional imaging methods have limitations with novel cancer therapies like targeted therapeutics and immunotherapy.
- Fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is not optimal for assessing immune therapies.
- There is a significant need for imaging biomarkers that can predict treatment response and patient prognosis.
Purpose of the Study:
- To review the development and potential of novel imaging agents for cancer management.
- To highlight the unmet need for pharmacodynamic and prognostic imaging biomarkers.
- To discuss the promise of radiolabeled antibodies and small molecules in precision oncology.
Main Methods:
- Review of preclinical and early human studies on novel imaging agents.
- Focus on radiolabeled antibodies and small molecules targeting specific cancer pathways (e.g., epidermal growth factor receptor).
- Exploration of immune-directed imaging agents and their potential as biomarkers.
Main Results:
- Radiolabeled antibodies and small molecules offer specific assessment of target expression and concentration.
- Early studies targeting the epidermal growth factor receptor pathway show potential.
- Immune-directed imaging agents show promise as biomarkers, with preliminary studies being encouraging.
Conclusions:
- Novel imaging agents, including radiolabeled antibodies and small molecules, are under development for cancer management.
- Targeted imaging of biomarkers like CA19.9 and CA-IX is being explored.
- Larger, well-designed studies are required to validate these novel agents as clinical biomarkers for patient management.
